Achieve Life Sciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Achieve Life Sciences, Inc. (ACHV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.81 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-24
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $3.81, a 13.73% increase from fiscal 2024.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $3.35, a 23.86% decline from fiscal 2023.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $4.40, a 35.20% decline from fiscal 2022.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $6.79, a 31.83% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $3.81 10-K · filed 2026-03-24 |
| 2024-12-31 | $3.35 10-K · filed 2025-03-11 |
| 2023-12-31 | $4.40 10-K · filed 2024-03-28 |
| 2022-12-31 | $6.79 10-K · filed 2023-03-16 |
| 2021-12-31 | $9.96 10-K · filed 2022-03-10 |
| 2020-12-31 | $8.76 10-K · filed 2021-03-11 |
| 2019-12-31 | $1.33 10-K · filed 2020-03-13 |
| 2018-12-31 | $2.05 10-K · filed 2019-03-14 |
| 2017-12-31 | $2.09 10-K · filed 2018-03-01 |
| 2016-12-31 | $0.53 10-K · filed 2017-02-23 |
| 2015-12-31 | $1.10 10-K · filed 2017-02-23 |
| 2014-12-31 | $6.52 10-K · filed 2017-02-23 |
| 2013-12-31 | $8.07 10-K · filed 2016-03-09 |
| 2012-12-31 | $9.86 10-K · filed 2015-03-26 |
| 2011-12-31 | $10.70 10-K · filed 2014-03-11 |
| 2010-12-31 | $11.08 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |